Lars-Gunnar Larsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/916134/publications.pdf

Version: 2024-02-01

45 papers	5,268 citations	257450 24 h-index	243625 44 g-index
48 all docs	48 docs citations	48 times ranked	10344 citing authors

#	Article	IF	Citations
1	MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner. Cancer Research Communications, 2022, 2, 182-201.	1.7	6
2	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Research Communications, 2022, 2, 110-130.	1.7	10
3	Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule. Frontiers in Molecular Biosciences, 2022, 9, .	3.5	3
4	The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells. Investigational New Drugs, 2021, 39, 587-594.	2.6	10
5	Methods to Study Myc-Regulated Cellular Senescence: An Update. Methods in Molecular Biology, 2021, 2318, 241-254.	0.9	3
6	Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence. Cell Cycle, 2021, 20, 23-38.	2.6	7
7	PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer. ELife, 2020, 9, .	6.0	15
8	MYC and RAS are unable to cooperate in overcoming cellular senescence and apoptosis in normal human fibroblasts. Cell Cycle, 2018, 17, 2697-2715.	2.6	13
9	A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation. Scientific Reports, 2018, 8, 10064.	3.3	85
10	MYC Modulation around the CDK2/p27/SKP2 Axis. Genes, 2017, 8, 174.	2.4	58
11	Interferon-Î³-induced p27KIP1 binds to and targets MYC for proteasome-mediated degradation. Oncotarget, 2016, 7, 2837-2854.	1.8	12
12	Targeting <i>MYC</i> Translation in Colorectal Cancer. Cancer Discovery, 2015, 5, 701-703.	9.4	30
13	Sin3b Interacts with Myc and Decreases Myc Levels. Journal of Biological Chemistry, 2014, 289, 22221-22236.	3.4	29
14	MYC Synergizes with Activated BRAFV600E in Mouse Lung Tumor Development by Suppressing Senescence. Cancer Research, 2014, 74, 4222-4229.	0.9	15
15	Methods to Study MYC-Regulated Cellular Senescence. Methods in Molecular Biology, 2013, 1012, 99-116.	0.9	2
16	<scp>CDK</scp>â€mediated activation of the <scp>SCF^{FBXO}</scp>²⁸ ubiquitin ligase promotes <scp>MYC</scp>â€driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Molecular Medicine, 2013, 5, 1067-1086.	6.9	61
17	The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E187-96.	7.1	226
18	Inhibition of the Intrinsic but Not the Extrinsic Apoptosis Pathway Accelerates and Drives Myc-Driven Tumorigenesis Towards Acute Myeloid Leukemia. PLoS ONE, 2012, 7, e31366.	2.5	21

#	Article	IF	Citations
19	Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Seminars in Cancer Biology, 2011, 21, 367-376.	9.6	119
20	Cellular senescenceâ€"A barrier against tumor development?. Seminars in Cancer Biology, 2011, 21, 347-348.	9.6	5
21	The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Experimental Cell Research, 2010, 316, 1429-1437.	2.6	89
22	Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nature Cell Biology, 2010, 12, 54-59.	10.3	218
23	Myc Is Required for Activation of the ATM-Dependent Checkpoints in Response to DNA Damage. PLoS ONE, 2010, 5, e8924.	2.5	59
24	Tipping the Balance: Cdk2 Enables Myc to Suppress Senescence. Cancer Research, 2010, 70, 6687-6691.	0.9	33
25	Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 58-63.	7.1	167
26	Cdk2: a key regulator of the senescence control function of Myc. Aging, 2010, 2, 244-250.	3.1	47
27	TGF-Î² enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity. Experimental Cell Research, 2009, 315, 3099-3111.	2.6	26
28	Combined IFN-Î³ and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in <i>MYCN</i>-amplified neuroblastoma cells. Molecular Cancer Therapeutics, 2007, 6, 2634-2641.	4.1	25
29	Drugâ€induced Mycâ€mediated apoptosis of cancer cells is inhibited by stress protein Hsp70. International Journal of Cancer, 2007, 121, 2615-2621.	5.1	24
30	SNIP1: Myc's New Helper in Transcriptional Activation. Molecular Cell, 2006, 24, 811-812.	9.7	7
31	Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature Methods, 2006, 3, 995-1000.	19.0	2,103
32	c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nature Cell Biology, 2005, 7, 303-310.	10.3	421
33	Mad 1 Inhibits Cell Growth and Proliferation but Does Not Promote Differentiation or Overall Survival in Human U-937 Monoblasts. Molecular Cancer Research, 2004, 2, 464-476.	3.4	7
34	Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene, 2003, 22, 351-360.	5.9	277
35	The F-Box Protein Skp2 Participates in c-Myc Proteosomal Degradation and Acts as a Cofactor for c-Myc-Regulated Transcription. Molecular Cell, 2003, 11, 1189-1200.	9.7	441
36	Implication of the ubiquitin/proteasome system in Myc-regulated transcription. Cell Cycle, 2003, 2, 403-7.	2.6	28

#	Article	IF	Citations
37	Interferon-? cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells. International Journal of Cancer, 2001, 94, 97-108.	5.1	26
38	c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood, 2000, 95, 2104-2110.	1.4	244
39	Posttranslational Regulation of Myc Function in Response to Phorbol Ester/Interferon-Î³â€“Induced Differentiation of v-Mycâ€“Transformed U-937 Monoblasts. Blood, 1999, 93, 3900-3912.	1.4	27
40	The basic region/helixâ€‰â€“â€‰loopâ€‰â€“â€‰helix/leucine zipper domain of Myc proto-oncoproteins: Function and regulation. Oncogene, 1999, 18, 2955-2966.	5.9	179
41	Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells. Oncogene, 1997, 15, 737-748.	5.9	38
42	The Role of Bcl-2 in the Pathogenesis of B Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1993, 11, 173-179.	1.3	35
43	Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. International Journal of Cancer, 1992, 50, 153-160.	5.1	13
44	C-Junis Induced to High Continuous Expression During Differentiation of Hematopoietic Cells and is Regulated Independently from C-Fos. Leukemia and Lymphoma, 1991, 4, 193-204.	1.3	4
45	Novel Allosteric Mechanism of P53 Activation by Small Molecules for Targeted Anticancer Therapy. SSRN Electronic Journal, 0, , .	0.4	0